Skip to main content

FDA recall, , Moderate risk

BD ChloraPrep Clear

BD ChloraPrep Clear may have an open or incomplete seal on the applicator packaging.

What happened

CareFusion 213, LLC, of El Paso, Texas, recalled BD ChloraPrep Clear, a sterile solution containing 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol, because affected product may exhibit an open or incomplete seal on the packaging of the applicator. The company began the recall on July 9, 2026, and the FDA added it to the Enforcement Report on July 15, 2026.

The product, sold in cartons of 60 x 1 mL applicators, was distributed nationwide in the U.S.A. The recall, involving 43,066,599 units, was classified by the FDA on July 15, 2026, and in the FDA's weekly enforcement report on July 22, 2026.

What to do

We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:

  1. Check the FDA or company notice for instructions specific to this product.
  2. Ask your pharmacist or doctor whether your lot is affected and what to do.

Is yours affected?

Match the NDC and lot code listed under your product.

An NDC (National Drug Code) is usually printed on the drug's label.

  1. BD ChloraPrep Clear

    NDC
    • 54365-400-31
    Lot code
    • 4062535
    • 4065201
    • 4066446

Recall details

Company began the recall
Sold in

U.S.A. Nationwide

Company
CareFusion 213, LLCEl Paso, Texas
Risk

Moderate risk

Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.

FDA Class II recall · How risk is rated

Event ID
99377
Recall number
D-0690-2026
Quantity recalled
43,066,599 units

All recalls from CareFusion 213, LLC

Timeline

FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.

  1. Company began the recall

  2. Added to FDA's Enforcement Report · Classified by FDA

  3. Listed on Recall Canary

  4. In FDA's weekly enforcement report

  5. Summary updated

Summary by Recall Canary, written with AI · summary updated Oct 2, 2026 · primary source: U.S. Food and Drug Administration (opens in a new tab)